---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063177"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-06-01T12:45:27+00:00"
generated_at: "2026-06-01T12:50:30.453868+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

## Summary
- 92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.
- EASI-90 rates: 44.4% at Week 4 and 51.9% at Week 8 for GX-03 vs 30.4% and 34.8% vehicle.
- No treatment-related serious adverse events, tolerability issues, or discontinuations reported.
- Enrollment nearing completion; company optimizing trial endpoints and planning FDA meeting.
- Detailed data to be presented at Jefferies Global Healthcare conference on June 4, 2026.

## SEC filing metadata
- accession: 0001213900-26-063177
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-06-01T12:45:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/0001213900-26-063177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026063177/ea0292880-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063177
- JSON: https://secwatch.observer/filing/0001213900-26-063177.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.